Microbix Biosystems Inc. (MBX) — closed signal from December 9, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 9, 2026.
Predicted vs. what happened
What happened
Reached its target in 37 days.
The thesis — published December 9, 2025
MBX is a small, risky healthcare company that looks like it could bounce back because many investors feel positive and the business actually sells diagnostic products. The stock shows signs of being very depressed while still above longer-term support. A new buyback and a partnership on HPV testing add real demand, though a big fund selling adds extra volatility.
Primary drivers
- Stock looks very depressed and may snap back up.
- Sells diagnostic products, so it has real revenue potential.
- Buyback and HPV test partnership should help demand.
- A big fund selling raises volatility and needs tight risk control.
How it played out
MBX: target reached in 37 days
Lyra published MBX at $31.38 on 2025-12-09 with a short-term thesis for 40% growth. The thesis pointed to a very depressed stock that could snap back up, diagnostic product revenue, a buyback, and an HPV testing partnership. It also noted that a big fund selling could add volatility and needed tight risk control.
Inside the window, MBX reached a peak of $44.89 on 2026-01-15, above the $43.93 target. The target was reached in 37 days. The stock later ended the window at $27.94 on 2026-03-09. The thesis played out, but the close was weak.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.